视觉与眼科学研究协会（ARVO）——2010年年会。为了视力：眼与视觉研究的未来——第二部分。

Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 2.

作者信息

Hookes Livia

机构信息

Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.

出版信息

IDrugs. 2010 Jul;13(7):430-2.

PMID:20582863

Abstract

The 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), held in Fort Lauderdale, FL, USA, included topics covering new therapeutic developments in the field of eye and vision research. This conference report highlights selected presentations on the development of OT-440 (Othera Pharmaceuticals Inc) for the potential treatment of glaucoma, an extended-release implant of brimonidine (pSivida Corp) for ocular hypertension, AR-12286 (Aerie Pharmaceuticals Inc) for ocular hypertension or glaucoma, AC-8 (Calmune Corp/RiboVax Biotechnologies SA) for ocular diseases following HSV infection, and fidarestat (Sanwa Kagaku Kenkyusho Co Ltd) and the recombinant proteins NOV and NOVCter (INSERM/University Rene Descartes) for corneal neovascularization.

摘要

在美国佛罗里达州劳德代尔堡举行的2010年视觉与眼科学研究协会（ARVO）年会涵盖了眼与视觉研究领域新治疗进展的诸多主题。本会议报告重点介绍了关于OT-440（Othera制药公司）用于青光眼潜在治疗的研发、溴莫尼定缓释植入剂（pSivida公司）用于高眼压症、AR-12286（Aerie制药公司）用于高眼压症或青光眼、AC-8（Calmune公司/RiboVax生物技术公司）用于单纯疱疹病毒感染后的眼部疾病，以及非达司他（三和化学研究所）和重组蛋白NOV与NOVCter（法国国家健康与医学研究院/勒内·笛卡尔大学）用于角膜新生血管形成的部分报告。